Gujarat Themis Biosyn incorporates step-down subsidiary in Ireland

Gujarat Themis Biosyn Limited has expanded its international footprint by incorporating a step-down subsidiary, Themis Biosyn Private Limited, in Ireland on June 16, 2026. The newly formed entity operates within the pharmaceutical industry and holds a share capital of 100 Euro. This strategic move aims to bolster the company's presence in the European market.

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Themis Biosyn Private Limited is a wholly owned subsidiary of Themis Biosyn Ireland Private Limited, which holds 100% of the shareholding.

Details regarding the incorporation were submitted to the BSE Limited and the National Stock Exchange of India Limited. The company clarified that the transaction does not fall under related party transactions, and no specific governmental or regulatory approvals were required for this incorporation.

The following table outlines the key details of the newly incorporated subsidiary:

Sr. No.	Particulars	Details
(a)	Name of the target entity	Name: Themis Biosyn Private Limited Country of Incorporation: Ireland Share capital: 100 Euro
(i)	Percentage of shareholding acquired	100% of the shareholding of Themis Biosyn Private Limited, a wholly owned subsidiary is held by Themis Biosyn Ireland Private Limited.
(j)	Brief background about the entity acquired	Date of Incorporation: 16 June, 2026 Date of receiving the Business registration extract: 16 June, 2026.

The Board of Directors of Gujarat Themis Biosyn approved the strategic expansion, with the intimation signed by Dinesh S. Patel, Chairman & Director. The company received the business registration extract for the new entity on the same date as its incorporation.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.95%	+0.07%	+10.39%	-1.41%	+17.80%	+57.54%

Gujarat Themis Biosyn Limited has cancelled the Board meeting scheduled for June 19, 2026, due to unavoidable circumstances. The company had previously convened the meeting to evaluate a proposal for raising funds through equity shares or various securities. The revised date for the Board meeting will be communicated to the stock exchanges in due course.

The earlier agenda included the consideration of issuing Compulsory Convertible Debentures, Optionally Convertible Debentures, and Non-Convertible Debentures. The proposed fund raising was intended to be conducted through a preferential issue on a private placement basis or any other permissible manner, subject to necessary approvals.

Regulatory Compliance

The intimation regarding the cancellation was submitted to BSE Limited and the National Stock Exchange of India Limited. The company stated that the revised date would be disclosed in compliance with the applicable timelines prescribed under Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.